Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
Bristol-Myers Squibb
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04349267CT.gov Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bms 986315 (this asset) | Bristol-Myers Squibb | P1/2 | CC · 42 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P4 | BB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Fluorouracilum | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | InSilico Medicine Hong Kong Limited | P4 | BB |
| Trametinib | Cancer Research UK | P2/3 | BB |
+42 more in the Cancer cohort
Other indications for Bms 986315
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bms 986315 in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bms-986315-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →